ATX inhibition by small inhibiting molecules like PF8380 is a rapidly evolving treatment strategy, which was used for chronic inflammation and cancer with a potential therapeutic benefit [44], as well as for treating air-pouch inflammation [23], collagen-induced arthritis [45], bleomycin-induced pulmonary inflammation and fibrosis [46], allergen-induced asthma [47], or metastasis of melanoma and breast cancer cells [45–52]. This evidence concerns the gene ENPP2 and melanoma.